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1. INTRODUCTION {#ccr31947-sec-0001}
===============

Nephronophthisis (NPHP) is a progressive renal disease that onsets during childhood or adolescence and presents with a range of clinical characteristics including polydipsia,polyuria, and secondary enuresis, that cause patients to progress to end‐stage renal disease (ESRD).[1](#ccr31947-bib-0001){ref-type="ref"} To date, more than 20 genes have been implicated to cause NPHP, which is predominantly inherited in an autosomal recessive manner.[2](#ccr31947-bib-0002){ref-type="ref"}, [3](#ccr31947-bib-0003){ref-type="ref"} *NPHP* genes encode proteins expressed by the primary cilia of the renal tubular epithelium and mediate intercellular and cell‐extracellular matrix signaling, cell adhesion, and cell polarity. In fact, NPHP is considered to be a ciliopathy, since it is caused by structural and functional damage of primary cilia, basal body, and centrosome functions.[3](#ccr31947-bib-0003){ref-type="ref"}, [4](#ccr31947-bib-0004){ref-type="ref"}

NPHP patients are classified as either infantile, juvenile, or adolescent‐type NPHP according to the age of onset. Specifically, infantile NPHP onsets between 0 and 3 years, whereas the average age of onset for juvenile and adolescent‐type NPHP is 13 and 19 years, respectively.[1](#ccr31947-bib-0001){ref-type="ref"} While most patients with *NPHP1‐*associated juvenile NPHP progress to ESRD by an average age of 18 years, a recent study reported that some do not exhibit ESRD until they reach adulthood.[5](#ccr31947-bib-0005){ref-type="ref"}

Autosomal dominant polycystic kidney disease (ADPKD) has similarly been shown to be a ciliopathy that is characterized by the progressive development and accumulation of numerous renal cysts, eventually leading to ESRD.[6](#ccr31947-bib-0006){ref-type="ref"} ADPKD is caused by mutations in *PKD1* and *PKD2,*which encode polycystin1 (PC1) and polycystin 2 (PC2) proteins, respectively, that are expressed in the cilia of renal tubular cells. PC1 normally functions to sense the flow of urine, and then transmits a signal to PC2, which is an intracellular calcium release channel. The resulting PC2‐mediated influx of calcium regulates the renal tubular diameter. Impairment of these functions by ADPKD‐causative mutations leads to cyst formation.

Herein, we report a patient with adult‐onset NPHP‐induced ESRD that was identified to harbor a homozygous full gene deletion of *NPHP1*and a heterozygous *PKD1*substitution.

2. CASE REPORT {#ccr31947-sec-0002}
==============

The patient was a 34‐year‐old Japanese man, whose family history included a father with hypertension, and a mother that suffered a subarachnoid hemorrhage, but which did not include either a consanguineous marriage or any incidence of renal cysts. At the age of 31, the patient presented with mild albuminuria, and a serum creatinine (Cr) level of 2.98 mg/dL. At the age of 34, the patient was admitted to hospital with a creatinine level of 8.2 mg/dL.

Upon admission, the patient\'s height, weight, and blood pressure were 179 cm, 58 kg, and 126/80 mm Hg, respectively. The patient exhibited anemia (Hb 8.2 g/dL), azotemia (Cr 8.38 mg/dL), hyperphosphatemia, metabolic acidosis, and secondary hyperparathyroidism; thus, he was diagnosed with ESRD. An abdominal ultrasonography revealed that, although the size of both kidneys appeared to be normal, the patient\'s renal parenchyma showed increased brightness. We performed a percutaneous renal biopsy; histologically, six of 16 glomeruli displayed global sclerosis, along with mild cellular infiltration, conspicuous interstitial fibrosis, renal tubular atrophy, and cystoid irregular dilation (Figure [1](#ccr31947-fig-0001){ref-type="fig"}), suggesting an NPHP diagnosis. We performed targeted sequencing using a next‐generation sequencer,[7](#ccr31947-bib-0007){ref-type="ref"} with the approval by the research ethics committee of Tokyo Medical and Dental University in accordance with the Declaration of Helsinki and the patient\'s written informed consent. A homozygous full gene deletion of *NPHP1* (NM_000272.3:g110879716‐110962709) was resultantly identified, as well as heterozygous substitutions in *PKD1* (NM_0001009944.2:c.6395T\>G(p.Phe2132Cys)) (Figure [2](#ccr31947-fig-0002){ref-type="fig"}), *BBS1*(NM_024649.4:c.908T\>C(p.Val303Ala))*,* and *INPP5E*(NM_019892.4:c.1652C\>T(p.Thr551Met))*.*

![Evaluation of renal biopsy specimens using light microscopy. The patients' (periodic acid‐Schiff‐stained) renal biopsy specimens displayed thickening of the renal tubular basement membrane (TBM), tubular atrophy, and tubulointerstitial fibrosis with chronic inflammation. As shown here, some tubules were found to be dilated, and the glomeruli were unaffected by the observed changes. Furthermore, the TBM can be seen to be irregularly thickened/thinned in certain areas, and there are numerous sections showing a transition between normal and thickened or thinner sections. TBM duplication was also evident. (Original magnification, ×40)](CCR3-7-336-g001){#ccr31947-fig-0001}

![Sequencing chromatogram showing the patient\'s heterozygous substitution (c. 6395T\>G, p.Phe2132Cys) in exon 15 of *PKD1*. Upper sequence, reference human *PKD1* sequence; lower sequence, patient mutant *PKD1* sequence](CCR3-7-336-g002){#ccr31947-fig-0002}

3. DISCUSSION {#ccr31947-sec-0003}
=============

The genetic analyses in our adult‐onset patient revealed a homozygous full gene deletion of*NPHP1*, which is typically associated with juvenile nephronophthisis.[3](#ccr31947-bib-0003){ref-type="ref"}, [4](#ccr31947-bib-0004){ref-type="ref"}, [8](#ccr31947-bib-0008){ref-type="ref"}, [9](#ccr31947-bib-0009){ref-type="ref"} Albeit rare, other similar patients of NPHP‐induced delayed/adult‐onset ESRD have previously been observed.[10](#ccr31947-bib-0010){ref-type="ref"}, [11](#ccr31947-bib-0011){ref-type="ref"}, [12](#ccr31947-bib-0012){ref-type="ref"}, [13](#ccr31947-bib-0013){ref-type="ref"} More recently, 26 (0.5%) patients harboring a homozygous *NPHP1* full gene deletion were identified among 5606 patients that underwent kidney transplantation.[5](#ccr31947-bib-0005){ref-type="ref"} The average age at which these patients developed ESRD was 30 years (range, 18‐61 years), and 54% of the patients were aged greater than 30 years at ESRD onset. In many of these previous reports, the presence of NPHP‐modifier genes was discussed as a probable cause of the late ESRD onset. In addition to the identified *NPHP1*full gene deletion, the patient was also shown to harbor heterozygous substitutions in *PKD1, BBS1,* and *INPP5E*. The *PKD1* substitution (p.Phe2132Cys) (dbSNP: rs150154235, <https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs>=150154235, <https://www.ncbi.nlm.nih.gov/clinvar/variation/431936/>) identified in this patient was previously reported in the PKD Mutation Database as a "likely pathogenic mutation".[14](#ccr31947-bib-0014){ref-type="ref"} Although the detected *BBS1* substitution (p.Val303Ala) (rs750668484 in NCBI (<https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs>=750668484) has been previously reported as a heterozygous mutation (AGVGD class, C25; SIFT prediction, deleterious; MAPP prediction, good), its pathological significance is not yet clear.[15](#ccr31947-bib-0015){ref-type="ref"} Likewise, the identified *INPP5E* substitution (p.Thr551Met) is to date considered to be a variant of uncertain significance (dbSNP: rs75342839; <https://www.ncbi.nlm.nih.gov/snp/75342839>, <https://preview.ncbi.nlm.nih.gov/clinvar/variation/373633/>). Each of these genetic mutations may have modulated the clinical course of the patient\'s NPHP via incurred epistatic effects, as has been previously proposed for many other hereditary disorders and ciliopathies. Indeed, while autosomal recessive disorders develop as a result of homozygous or compound heterozygous mutations, their phenotypes are often modified by the presence of a third gene mutation. For example, a family patient of ciliopathic Bardet‐Biedl syndrome (BBS) was previously reported, in which affected members harbored causative mutations in *BBS1, BBS2,*and/or *BBS6*, as well as additional heterozygous mutations in the other *BBS*genes, which is considered to enhance the disease phenotype.[16](#ccr31947-bib-0016){ref-type="ref"}, [17](#ccr31947-bib-0017){ref-type="ref"} Further, studies using zebrafish have shown that heterozygous C430T mutations in *MGC1203*, which is a gene shown to be related to *BBS4*, similarly enhance the BBS phenotype.[18](#ccr31947-bib-0018){ref-type="ref"} Likewise, in NPHP, additional heterozygous mutations in other *NPHP* genes have been shown to modulate the disease phenotype.[19](#ccr31947-bib-0019){ref-type="ref"}, [20](#ccr31947-bib-0020){ref-type="ref"}, [21](#ccr31947-bib-0021){ref-type="ref"} Crossing homozygous *Nphp1*‐knockout (*Nphp* ^‐/‐^) with heterozygous *Ah1‐*knockout mice (*Ah1* ^+/−^) (the causative gene in Joubert syndrome) has been shown to enhance the development of retinal degenerative lesions.[22](#ccr31947-bib-0022){ref-type="ref"}

While the pathological significances of the *BBS1*and *INPP5E* mutations are unknown, evidence suggests that the *PKD1*mutation may be a contributing factor to NPHP disease progression. As an autosomal dominant disorder, ADPKD is induced by a heterozygous *PKD1*mutation that is present in the whole body; however, a heterozygous *PKD1*mutation does not lead to cyst formation because of the existence of normal allele of *PKD1*. When somatic mutations in the normal *PKD1* allele, that is proposed as "two‐hit theory", occur in the renal tubular cells, PC1 function in the cells is lost, thereby leading to cyst formation.[6](#ccr31947-bib-0006){ref-type="ref"}

Although both nephrocystin 1, which is encoded by*NPHP1*, and PC1 function as ciliary proteins, they are also known to have cilia‐independent functions. Interestingly, a previous study showed that the polyproline motif‐2 present in the PC1 C‐terminal binds to the nephrocystin 1 SH3 domain to control the apoptosis of renal tubular epithelial cells.[23](#ccr31947-bib-0023){ref-type="ref"} PC1 has also been shown to be capable of independently suppressing cell proliferation, without interacting with nephrocystin 1. We hypothesize that the occurrence of this independent function in the renal tubular cells may have acted as an epistatic protective effect in the present patient. Renal tubular cells harboring both the homozygous *NPHP1* deletion and heterozygous *PKD1* mutation would be unable to maintain controlled apoptosis; however, in the absence of any further somatic mutations, the remaining functional *PKD1* allele would be sufficient to suppress excess cell proliferation. The introduction of additional somatic *PKD1* mutations in even a small portion of the patient\'s renal tubular cells would induce a loss of PC1 function, rendering the cells unable to suppress proliferation, and thus, potentially leading to cell immortalization.[24](#ccr31947-bib-0024){ref-type="ref"} Cellular functions not related to nephrocystin 1 and PC1 would be retained in these proliferated renal tubular cells, contributing to the maintenance of renal function, and thereby delaying the onset of ESRD.

In conclusion, we here describe a patient with delayed‐onset NPHP that was caused by a homozygous *NPHP1* full gene deletion, and possibly modified by heterozygous mutations in cyst formation‐related genes. An epistatic action induced via the detected *PKD1* mutation likely ameliorated NPHP disease progression. Although epistatic effects have regularly been reported in ciliopathies, we have no evidence of the mechanism of an ameliorating effect of the *PKD1* variant on the *NPHP1*‐null phenotype. Therefore, we need to validate this finding on larger cohorts of late onset NPHP type 1.
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